Population pharmacokinetics of etoposide: Application to therapeutic drug monitoring
In: Therapeutic drug monitoring, Jg. 24 (2002), Heft 6, S. 709-714
Online
academicJournal
- print, 31 ref
Zugriff:
Antineoplastic agent etoposide (VP16) displays narrow therapeutic index and erratic pharmacokinetics, and dose individualization is a convenient way for overcoming the interpatient variability, so as to maintain the drug exposure within a therapeutic range. The authors proposed a population-based Bayesian methodology to adjust routinely VP16 dosage when given as a 5-day infusion. The mean VP16 pharmacokinetic parameters of the reference population calculated from 14 patients following the two-stage method were CL = 1.92 ± 0.512 L/h and t1/2 = 6.7 ± 2 hours. The reference population was next used prospectively for Bayesian dose individualization for 25 patients (47 courses) undergoing 5-day infusions of VP16. Resulting steady-state concentrations proved to be successfully adjusted to the target values in 77% of the courses. Therefore, the method presented here meets the requirements for routine therapeutic drug monitoring of VP16, a major anticancer drug extensively used in clinical oncology.
Titel: |
Population pharmacokinetics of etoposide: Application to therapeutic drug monitoring
|
---|---|
Autor/in / Beteiligte Person: | CICCOLINI, Joseph ; MONJANEL-MOUTERDE, Suzanne ; BUN, Sok-Siya ; BLANC, Chantal ; DUFFAUD, Florence ; FAVRE, Roger ; DURAND, Alain |
Link: | |
Zeitschrift: | Therapeutic drug monitoring, Jg. 24 (2002), Heft 6, S. 709-714 |
Veröffentlichung: | Hagerstown, MD: Lippincott Williams & Wilkins, 2002 |
Medientyp: | academicJournal |
Umfang: | print, 31 ref |
ISSN: | 0163-4356 (print) |
Schlagwort: |
|
Sonstiges: |
|